Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 3
Submit an article Journal homepage
421
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

The effects of different schedules of bortezomib, melphalan, and prednisone for patients with newly diagnosed multiple myeloma who are transplant ineligible: a matching-adjusted indirect comparison

Maria-Victoria MateosHaematology Department, University Hospital of Salamanca/IBSAL, Salamanca, Spain; ORCID Iconhttp://orcid.org/0000-0003-2390-1218View further author information
ORCID Icon,
Jesus San-MiguelClínica Universidad de Navarra-CIMA, IDISNA, CIBERONC, Pamplona, Spain; ORCID Iconhttp://orcid.org/0000-0002-9183-4857View further author information
ORCID Icon,
Hartmut GoldschmidtInternal Medicine V and National Center of Tumor Diseases (NCT), University Clinic Heidelberg, Heidelberg, Germany; ORCID Iconhttp://orcid.org/0000-0003-0961-0035View further author information
ORCID Icon,
Pieter SonneveldDepartment of Haematology, Erasmus MC, Rotterdam, The Netherlands; ORCID Iconhttp://orcid.org/0000-0002-0808-2237View further author information
ORCID Icon,
Meletios A. DimopoulosDepartment of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece; ORCID Iconhttp://orcid.org/0000-0001-8990-3254View further author information
ORCID Icon,
Bart HeegIngress Health, Rotterdam, The Netherlands; ORCID Iconhttp://orcid.org/0000-0002-9226-3232View further author information
ORCID Icon,
Mahmoud HashimIngress Health, Rotterdam, The Netherlands; ORCID Iconhttp://orcid.org/0000-0002-5775-9590View further author information
ORCID Icon,
William DeraedtOncology R&D, Janssen Research & Development, Beerse, Belgium; ORCID Iconhttp://orcid.org/0000-0003-1414-2387View further author information
ORCID Icon,
Peter HuStatistical Programming (Haematology), Janssen Research & Development, LLC, Raritan, NJ, USA; ORCID Iconhttp://orcid.org/0000-0002-4061-8484View further author information
ORCID Icon,
Annette LamGlobal Market Access and Health Policy, Janssen Global Services, LLC, Raritan, NJ, USAORCID Iconhttp://orcid.org/0000-0003-2037-3464View further author information
ORCID Icon &
Jianming HeGlobal Market Access and Health Policy, Janssen Global Services, LLC, Raritan, NJ, USACorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-5015-3713View further author information
ORCID Icon show all
Pages 680-690 | Received 09 Aug 2019, Accepted 28 Sep 2019, Published online: 05 Nov 2019

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Iuliana Vaxman & Morie Gertz. (2020) Non-transplant eligible multiple myeloma: deciphering optimal first line regimens. Leukemia & Lymphoma 61:3, pages 504-506.
Read now

Articles from other publishers (6)

Rahul Banerjee, Bo Wang, Larry D. AndersonJrJr, Georgia McCaughan, Nikita Mehra, Andrew J. Cowan, S. Vincent Rajkumar & Gurbakhash Kaur. (2023) Once-weekly bortezomib as the standard of care in multiple myeloma: results from an international survey of physicians. Blood Cancer Journal 13:1.
Crossref
Masaki Ri, Shinsuke Iida, Dai Maruyama, Aya Sakabe, Ryo Kamei, Takuto Nakashima, Masahiro Tohkin, Satoshi Osaga, Kensei Tobinai, Noriko Fukuhara, Kana Miyazaki, Norifumi Tsukamoto, Hideki Tsujimura, Makoto Yoshimitsu, Kenichi Miyamoto, Kunihiro Tsukasaki & Hirokazu Nagai. (2021) HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1). Cancer Science 112:12, pages 5011-5019.
Crossref
Jian Li & Henry Chan. (2021) Management of Multiple Myeloma in Older Patients. EMJ Hematology, pages 69-81.
Crossref
Mahmoud Hashim, Talitha Vincken, Florint Kroi, Samron Gebregergish, Mike Spencer, Jianping Wang, Tobias Kampfenkel, Annette Lam & Jianming He. (2021) A systematic review of noninferiority margins in oncology clinical trials. Journal of Comparative Effectiveness Research 10:6, pages 443-455.
Crossref
Philippe Moreau, Cyrille Hulin, Sonja Zweegman, Mahmoud Hashim, Yannan Hu, Bart Heeg, Carla Boer, Veronique Vanquickelberghe, Tobias Kampfenkel, Jianming He, Annette Lam, Sarah Cote & Pieter Sonneveld. (2020) Comparative efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) without and with daratumumab (D‐VTd) in CASSIOPEIA versus VTd in PETHEMA/GEM in transplant‐eligible patients with newly diagnosed multiple myeloma, using propensity score matching. eJHaem 2:1, pages 66-80.
Crossref
Pieter Sonneveld, María‐Victoria Mateos, Adrian Alegre, Thierry Facon, Cyrille Hulin, Mahmoud Hashim, Talitha Vincken, Tobias Kampfenkel, Sarah Cote, Jianming He, Annette Lam & Philippe Moreau. (2020) Matching‐adjusted indirect comparison of efficacy and safety of bortezomib, thalidomide, and dexamethasone (VTd) as per label compared with modified VTd dosing schedules in patients with newly diagnosed multiple myeloma who are transplant eligible. eJHaem 1:2, pages 481-488.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.